Antitumor Activity of Axitinib in Lung Carcinoids: A Preclinical Study

被引:2
作者
Dicitore, Alessandra [1 ]
Gaudenzi, Germano [2 ]
Carra, Silvia [3 ]
Cantone, Maria Celeste [2 ]
Oldani, Monica [2 ]
Saronni, Davide [1 ]
Borghi, Maria Orietta [4 ,5 ]
Grotteschi, Jacopo [1 ]
Persani, Luca [1 ,3 ]
Vitale, Giovanni [1 ,2 ]
机构
[1] Univ Milan, Dept Med Biotechnol & Translat Med, I-20122 Milan, Italy
[2] Ist Auxol Italiano, IRCCS, Lab Geriatr & Oncol Neuroendocrinol Res, Milan I-20145, Italy
[3] Ist Auxol Italiano, IRCCS, Lab Endocrine & Metab Res, I-20145 Milan, Italy
[4] Univ Milan, Dept Clin Sci & Community Hlth, I-20122 Milan, Italy
[5] Ist Auxol Italiano, IRCCS, Expt Lab Immuno Rheumatol, I-20145 Milan, Italy
关键词
lung carcinoid; tyrosine kinase inhibitors; axitinib; cell cycle; apoptosis; zebrafish; tumor xenograft; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; PHASE-II; NEUROENDOCRINE TUMORS; MICROVASCULAR DENSITY; ENDOCRINE TUMORS; OPEN-LABEL; ANGIOGENESIS; EXPRESSION; SUNITINIB;
D O I
10.3390/cancers15225375
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Lung carcinoids (LCs) are categorized as low- and intermediate-grade neuroendocrine tumors. Surgery is effective for localized LCs with a favorable prognosis. However, there is a pressing need for new treatments for unresectable and metastatic LCs. This study explored the potential antitumor effects of axitinib using both in vitro (immortalized cell lines) and in vivo (zebrafish) LC models. Axitinib demonstrated significant antitumor activity by reducing cell viability, inducing cell cycle arrest, and promoting cell death. Moreover, axitinib had a notable impact on crucial processes in tumor progression, including tumor-induced angiogenesis and invasiveness.Abstract Lung carcinoids (LCs) comprise well-differentiated neuroendocrine tumors classified as typical (TCs) and atypical (ACs) carcinoids. Unfortunately, curative therapies remain elusive for metastatic LCs, which account for 25-30% of cases. This study evaluated the antitumor activity of axitinib (AXI), a second-generation tyrosine kinase inhibitor selectively targeting vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3) in human lung TC (NCI-H727, UMC-11, NCI-H835) and AC (NCI-H720) cell lines. In vitro and in vivo (zebrafish) assays were performed following AXI treatment to gather several read-outs about cell viability, cell cycle, the secretion of proangiogenic factors, apoptosis, tumor-induced angiogenesis and migration. AXI demonstrated relevant antitumor activity in human LC cells, with pronounced effects observed in UMC-11 and NCI-H720, characterized by cell cycle perturbation and apoptosis induction. AXI significantly hindered tumor induced-angiogenesis in Tg(fli1a:EGFP)y1 zebrafish embryos implanted with all LC cell lines and also reduced the invasiveness of NCI-H720 cells, as well as the secretion of several proangiogenic factors. In conclusion, our study provides initial evidence supporting the potential anti-tumor activity of AXI in LC, offering a promising basis for future investigations in mammalian animal models and, eventually, progressing to clinical trials.
引用
收藏
页数:16
相关论文
共 50 条
  • [31] Antitumor activity of MEK and PI3K inhibitors against malignant pleural mesothelioma cells in vitro and in vivo
    Miyoshi, Seigo
    Hamada, Hironobu
    Hamaguchi, Naohiko
    Kato, Aki
    Katayama, Hitoshi
    Irifune, Kazunori
    Ito, Ryoji
    Miyazaki, Tatsuhiko
    Okura, Takafumi
    Higaki, Jitsuo
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (02) : 449 - 456
  • [32] Antitumor and Antiangiogenic Activity of Cediranib in a Preclinical Model of Renal Cell Carcinoma
    Medinger, Michael
    Esser, Norbert
    Zirrgiebel, Ute
    Ryan, Anderson
    Juergensmeier, Juliane M.
    Drevs, Joachim
    ANTICANCER RESEARCH, 2009, 29 (12) : 5065 - 5076
  • [33] Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells
    Martinelli, Erika
    Troiani, Teresa
    Morgillo, Floriana
    Rodolico, Gabriella
    Vitagliano, Donata
    Morelli, Maria Pia
    Tuccillo, Concetta
    Vecchione, Loredana
    Capasso, Anna
    Orditura, Michele
    De Vita, Ferdinando
    Eckhardt, S. Gail
    Santoro, Massimo
    Berrino, Liberato
    Ciardiello, Fortunato
    CLINICAL CANCER RESEARCH, 2010, 16 (20) : 4990 - 5001
  • [34] Anticancer activity of tolfenamic acid in medulloblastoma: a preclinical study
    Eslin, Don
    Lee, Chris
    Sankpal, Umesh T.
    Maliakal, Pius
    Sutphin, Robert M.
    Abraham, Liz
    Basha, Riyaz
    TUMOR BIOLOGY, 2013, 34 (05) : 2781 - 2789
  • [35] Reduced apurinic/apyrimidinic endonuclease activity enhances the antitumor activity of oxymatrine in lung cancer cells
    Wang, Zhiqiang
    Xu, Wenya
    Lin, Ziying
    Li, Chunyan
    Wang, Yahong
    Yang, Lawei
    Liu, Gang
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2016, 49 (06) : 2331 - 2340
  • [36] Immune Checkpoint Blockade in Lung Carcinoids with Aggressive Behaviour: One More Arrow in Our Quiver?
    Di Molfetta, Sergio
    Feola, Tiziana
    Fanciulli, Giuseppe
    Florio, Tullio
    Colao, Annamaria
    Faggiano, Antongiulio
    JOURNAL OF CLINICAL MEDICINE, 2022, 11 (04)
  • [37] Antitumor activity of an adenovirus harboring human IL-24 in colon cancer
    Chang, Shujian
    Yang, Jicheng
    Chen, Weichang
    Xie, Yufeng
    Sheng, Weihua
    MOLECULAR BIOLOGY REPORTS, 2011, 38 (01) : 395 - 401
  • [38] Sex-based differences in the outcomes of patients with lung carcinoids
    Abdel-Rahman, Omar
    Ghosh, Sunita
    Fazio, Nicola
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (07) : 523 - 531
  • [39] Axitinib, a selective inhibitor of vascular endothelial growth factor receptor, exerts an anticancer effect in melanoma through promoting antitumor immunity
    Zhang, Xiaohua
    Fang, Xianying
    Gao, Zhenzhen
    Chen, Wei
    Tao, Feifei
    Cai, Peifen
    Yuan, Huaqin
    Shu, Yongqian
    Xu, Qiang
    Sun, Yang
    Gu, Yanhong
    ANTI-CANCER DRUGS, 2014, 25 (02) : 204 - 211
  • [40] Lymphadenectomy for lung carcinoids: Which factors may predict nodal upstaging? A multi centric, retrospective study
    Chiappetta, Marco
    Lococo, Filippo
    Sperduti, Isabella
    Cusumano, Giacomo
    Terminella, Alberto
    Fournel, Ludovic
    Guerrera, Francesco
    Filosso, PierLuigi
    Tabacco, Diomira
    Nicosia, Samanta
    Alifano, Marco
    Gallina, Filippo
    Facciolo, Francesco
    Margaritora, Stefano
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (03) : 588 - 598